Advertisement

AstraZeneca's Blockbuster Lung Cancer Drug Has a Huge Sales Boost Ahead

AstraZeneca's Blockbuster Lung Cancer Drug Has a Huge Sales Boost Ahead

Recently reported clinical trial data on Tagrisso shows that it lowers the risk of disease recurrence or death by 83% for some classes of lung cancer patients.